http://rdf.ncbi.nlm.nih.gov/pubchem/patent/JP-2008516936-A
Outgoing Links
| Predicate | Object |
|---|---|
| classificationCPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P43-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P3-10 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07D403-12 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07D231-40 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07D213-80 |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07D231-40 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07D213-80 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-4155 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-415 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P43-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P3-10 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07D403-12 |
| filingDate | 2005-10-11-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationDate | 2008-05-22-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | JP-2008516936-A |
| titleOfInvention | Phenoxybenzamide compounds useful in the treatment of type 2 diabetes and obesity |
| abstract | Formula (I) [R 1 is methoxymethyl; R 2 is selected from —C (O) NR 4 R 5 , —SO 2 NR 4 R 5 , —S (O) p R 4 and HET-2; HET-1 Is an optionally substituted C-linked 5 or 6 membered heteroaryl ring; HET-2 is an optionally substituted C- or N-linked 4, 5 or 6 membered heterocyclyl ring R 3 is selected from halo, fluoromethyl, difluoromethyl, trifluoromethyl, methyl, methoxy and cyano; R 4 is, for example, hydrogen, optionally substituted (1-4C) alkyl and HET-2; is selected from; R 5 is hydrogen or (1-4C) alkyl; or R 4 and R 5, together with the nitrogen atom to which they are attached, a heterocyclyl ring as defined by HET-3 HET-3 is, for example, an optionally substituted N-linked 4, 5 or 6 membered saturated or partially unsaturated heterocyclyl ring; p is 0 (independently for each designation) 1 or 2; m is 0 or 1; n is 0, 1 or 2; provided that when m is 0, n is 1 or 2], or a salt thereof, a pro Drugs and their solvates are described. Their use as GLK activators, pharmaceutical compositions containing them, and methods for their production are also described. |
| priorityDate | 2004-10-16-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 563.